Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis
详细信息 查看全文
- 作者：David Ghez ; Jean-Baptiste Micol ; Florence Pasquier ; Nathalie Auger ; V茅ronique Saada ; Marc Spentchian ; Jean-Christophe Ianotto ; Jean-Henri Bourhis ; Anelyse Bennaceur-Griscelli ; Christine Terr茅 ; Sylvie Castaigne ; Sophie Rigaudeau ; Philippe Rousselot ; St茅phane de Botton
- 关键词：Chronic myelogenous leukaemia ; Blast phase ; Tyrosine kinase inhibitors
- 刊名：European Journal of Cancer
- 出版年：November, 2013
- 年：2013
- 卷：49
- 期：17
- 页码：3666-3670
- 全文大小：242 K
文摘
Even in the tyrosine kinase inhibitors era, the prognosis of patients with chronic myeloid leukaemia in myeloid blast crisis remains dismal with few patients surviving longer than 6 months. Here we report the cases of 5 patients treated with the combination of 5-azacytidine and tyrosine kinase inhibitors for myeloid blast crisis CML. All patients achieved a complete haematological response including two with a complete cytogenetic and major molecular response. Two patients underwent an allogeneic stem cell transplantation. One died from relapse 34 months from diagnosis. The second is alive and free from disease at 11 months from diagnosis. The other 3 patients are still in complete haematological response after 15, 24 and 33 months of follow-up. These results suggest that the combination has a significant activity in myeloid blast crisis and may increase survival.